EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias


, : Electrophysiologic effects clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias. American Journal of Cardiology 59(4): 307-312

The electrocardiographic and electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol therapy were examined in 34 patients with recurrent supraventricular tachyarrhythmias (SVT) undergoing electrophysiologic evaluation. Programmed electrical stimulation was performed in the control (drug-free) state, after infusion of intravenous nadolol (mean dose 0.09 .+-. 0.03 mg/kg) and chronic oral nadolol therapy in patients who responded to intravenous nadolol (mean dose 83 .+-. 12 mg for 5 days). Intravenous nadolol administration prolonged mean sinus cycle length (p = 0.009), mean PR interval (p = 0.001) and mean AH interval (p = 0.001), with no significant electrophysiologic effects in the atrium, ventricle or accessory bypass tracts. Oral nadolol had similar electrocardiographic and electrophysiologic effects, but of lesser magnitude. Intravenous nadolol resulted in complete suppression of induced SVT in 78% of patients with sinus and atrioventricular nodal reentrant tachycardia and 11% of patients with atrioventricular (AV) reentrant tachycardia (p < 0.001). Partial responses were frequent in intraatrial or AV reentrant tachycardia (37%). Oral nadolol suppressed induction of SVT in patients who responded to intravenous nadolol. Adverse reactions to intravenous and oral nadolol were infrequent.sbd.6% and 8%, respectively.sbd.and usually did not require drug withdrawal. Intravenous nadolol is highly effective in sinus and AV nodal reentrant tachycardia, and a successful electrophysiologic response to it predicts efficacy of long-term oral nadolol therapy. It has limited efficacy alone in AV reentrant tachycardia and should be considered in combination with other antiarrhythmic therapy in this type of SVT.

Accession: 005349281

PMID: 3812280

DOI: 10.1016/0002-9149(87)90804-6

Download PDF Full Text: Electrophysiologic effects clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Mehta A.V.; Chidambaram B., 1992: Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children. The efficacy and safety of oral nadolol in supraventricular tachycardia were evaluated prospectively in 27 children (median age 5.5 years). Fifteen patients had an unsuccessful trial of digoxin therapy. Intravenous nadolol was given to seven patie...

Abdollah H.; Brugada P.; Green M.; Wehr M.; Wellens H.J.J., 1984: Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias. The electrophysiologic effects and clinical efficacy of i.v. and oral encainide were studied in 13 patients with accessory atrioventricular (AV) pathway (7 overt, 1 intermittent and 5 concealed) and drug-resistant supraventricular arrhythmias (5 p...

You-Kai, Y.-Xiaowei; Ren-Hongzhi, 1996: Clinical efficacy and safety of intravenous esmolol in the treatment of supraventricular tachyarrhythmias: Multiple centers analysis of 309 cases. To evaluate the antiarrhythmic effect and safetiness of esmolol, we observed 309 patients with supraventricular tachyarrthmia from 8 medical centers, including atria fibrillation or flutter, paroxysmal supraventricular tachycardia, automatic atria...

Olukotun, A.Y.; Klein, G.J., 1987: Efficacy and safety of intravenous nadolol for supraventricular tachycardia. In a double-blind, placebo-controlled, parallel trial of intravenous nadolol in the treatment of sustained supraventricular tachycardia (SVT), 29 patients (20 men, 9 women) were studied. Mean age was 55 years and all patients were required to have...

Sahar, D.I.; Reiffel, J.A.; Bigger, J.T.; Squatrito, A.; Kidwell, G.A., 1989: Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias. The efficacy, safety, and electrophysiologic effects of intravenous and oral d-sotalol, an investigational class III antiarrhythmic agent, are not yet well characterized. We evaluated the electrophysiologic, antiarrhythmic, and hemodynamic effects...

Sung R.J.; Karagounis L.; Das G.; Falk R.; Platia E.; Hanyok J.; Archibald D.; Sotalol Multicent Study Group, 1992: Intravenous sotalol for the treatment of supraventricular tachyarrhythmias safety and efficacy. Journal of the American College of Cardiology 19(3 SUPPL A): 220A

Cockrell J.L.; Fan W.; Sung R.J., 1991: Safety and efficacy of intravenous sotalol in terminating supraventricular tachyarrhythmias. Journal of the American College of Cardiology 17(2 SUPPL A): 56A

Vietti Ramus G.; Veglio F.; Marchisio U.; Burzio P.; Latini R., 1992: Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. The safety and efficacy of short intravenous therapy with amiodarone were evaluated in 44 patients (24 males, 20 females), aged 21-84 years, with supraventricular tachyarrhythmias newly arisen in less than 24 hours. The study group consisted of 15...

Seth, S.; Mittal, A.; Goel, P.; Wasir, H.S., 1996: Low-dose intravenous diltiazem--efficacy and safety in supraventricular tachyarrhythmias. Intravenous diltiazem has been used to rapidly reduce ventricular rate in patients with supraventricular tachyarrhythmias (SVTs). This study assesses the efficacy and safety of a low-dose (0.1 mg/kg) intravenous bolus of diltiazem on the heart rat...

Fujiki, A.; Tani, M.; Mizumaki, K.; Shimono, M.; Inoue, H., 1994: Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. The electrophysiologic effects of intravenous (i.v.) E-4031, a new class III antiarrhythmic drug, were evaluated in 15 patients with supraventricular tachyarrhythmias (11 men, 4 women; mean age 41 +- 19 (SD) years). Eleven patients had accessory a...